GlassScriptPhysician profile
Constance Marie Irick
NPI 1346235272
$19,854.65
in general payments reported to CMS, 2019-2025
78 companies · $2,836 in 2025
The $2,836 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $2,507 · 2021: $3,059 · 2022: $3,250 · 2023: $3,137 · 2024: $2,827 · 2025: $2,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,716 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,715.69 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,181.11 | 2019-2025 | |
| Pfizer INC. | $2,033.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,708.62 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,618.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,471.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $764.54 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $732.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $642.60 | 2019-2024 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $484.18 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $476.09 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Biohaven Pharmaceutical Holding Company LTD. | $460.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $401.09 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $310.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.79 | 2019-2025 | Trintellix |
| Allergan, INC. | $280.96 | 2020 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Irick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.